Dengue Vaccines
Live-attenuated chimeric vaccines
This page catalogs 2 dengue vaccine products. Dengue vaccines use chimeric live-attenuated technology and have complex eligibility requirements due to the risk of antibody-dependent enhancement (ADE) in seronegative individuals — a safety consideration that shaped both products' regulatory pathways.
Last updated: April 2026.
Dengue Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Dengvaxia | CYD-TDV live-attenuated tetravalent dengue | Sanofi Pasteur | Live-attenuated chimeric viral | FDA Licensed, 2019 | Only for seropositive individuals ≥9y |
| Qdenga | TAK-003 live-attenuated tetravalent dengue | Takeda | Live-attenuated chimeric viral | EMA Authorized, 2022 | EU/Indonesia approval 2022-23 |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and EMA Medicines database. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.